The timing of serum infliximab loss, or the appearance of antibodies to infliximab (ATI), is related with the clinical activity in ATI-positive patients with rheumatoid arthritis treated with infliximab

被引：7
|
作者：
Plasencia, Ch [1 ]
Pascual-Salcedo, D. [2 ]
Alcocer, P. [1 ]
Bonilla, M. G. [1 ]
Villalba, A. [1 ]
Peiteado, D. [1 ]
Arribas, F. [2 ]
Diez, J. [3 ]
Lopez-Casla, M. T. [2 ]
Martin-Mola, E. [1 ]
Balsa, A. [1 ]
机构：
[1] Paz Univ Hosp Idipaz, Dept Rheumatol, Paseo Castellana 261, Madrid 28046, Spain
[2] Paz Univ Hosp Idipaz, Immunol Unit, Madrid, Spain
[3] Paz Univ Hosp Idipaz, Stat Dept, Madrid, Spain
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 72卷 / 11期
关键词：
Anti-TNF; Rheumatoid Arthritis; Treatment; IMMUNOGENICITY;
D O I：
10.1136/annrheumdis-2013-203353
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1888 / 1890
页数：3
相关论文
共 50 条
  • [41] Circulating bioactive TNF in rheumatoid arthritis patients treated with infliximab: link to clinical response
    H Marotte
    P Miossec
    Arthritis Res Ther, 5
  • [42] Circulating bioactive TNF in rheumatoid arthritis patients treated with infliximab: link to clinical response
    Marotte, H
    Miossec, P
    ARTHRITIS RESEARCH & THERAPY, 2003, 5 (Suppl 1) : S15 - S15
  • [43] Autoimmunity is not associated with antibodies to infliximab in patients with early rheumatoid arthritis.
    Rojas, JR
    Wagner, CL
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S568 - S569
  • [44] Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy
    De Rycke, L
    Kruithof, E
    Van Damme, N
    Hoffman, IEA
    Van den Bossche, N
    Van den Bosch, F
    Veys, EM
    De Keyser, F
    ARTHRITIS AND RHEUMATISM, 2003, 48 (04): : 1015 - 1023
  • [45] Circulating bioactive TNFalpha in rheumatoid arthritis patients treated with infliximab: Link to clinical response
    Marotte, H
    Miossec, P
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 181 - 182
  • [46] Investigating the link between disease activity and infliximab serum levels in rheumatoid arthritis patients
    Valor, L.
    Hernandez-Florez, D.
    de la Torre, I.
    del Rio, T.
    Nieto, J. C.
    Gonzalez, C.
    Lopez-Longo, F. J.
    Monteagudo, I.
    Llinares, F.
    Rosas, J.
    Garrido, J.
    Naredo, E.
    Carreno, L.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2015, 33 (06) : 805 - 811
  • [47] Monitoring patients treated with anti-TNF- biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies
    Svenson, M.
    Geborek, P.
    Saxne, T.
    Bendtzen, K.
    RHEUMATOLOGY, 2007, 46 (12) : 1828 - 1834
  • [48] ESTABLISHING CUT-OFF OF INFLIXIMAB LEVELS AND ANTI-INFLIXIMAB ANTIBODIES BY COMMERCIAL ELISA IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Hernandez, Diana
    Valor, Lara
    de la Torre, Inmaculada
    Martinez, Lina
    Carlos Nieto, Juan
    del Rio, Tamara
    Naredo, Esperanza
    Gonzalez, Carlos
    Lopez-Longo, Javier
    Montoro, Maria
    Monteagudo, Indalecio
    Carreno, Luis
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : A11 - A11
  • [49] Modification of neutrophil function by plasma of rheumatoid arthritis patients treated with infliximab
    Dain, L
    Braun-Moscovici, Y
    Baum, E
    Nahir, AM
    Hoffer, E
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2006, 24 (01) : 38 - 44
  • [50] Bone tissue metabolism in rheumatoid arthritis patients treated with infliximab and methotrexate
    Zon-Giebel, A
    Kucharz, E
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 221 - 221
12345